AAV gene therapy company AskBio secures $235m investment

This article was originally published here

The investment in AskBio includes an amount of $225m committed by global alternative asset firm TPG Capital and life sciences investment firm Vida Ventures in exchange of a

The post AAV gene therapy company AskBio secures $235m investment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply